Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer

Author:

Paffenholz Stella V.12,Salvagno Camilla34,Ho Yu-Jui1,Limjoco Matthew1,Baslan Timour1,Tian Sha1,Kulick Amanda5,de Stanchina Elisa5,Wilkinson John E.6,Barriga Francisco M.1,Zamarin Dmitriy7,Cubillos-Ruiz Juan R.348,Leibold Josef1910,Lowe Scott W.111ORCID

Affiliation:

1. Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065

2. Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065

3. Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY 10065

4. Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065

5. Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065

6. Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI 48109

7. Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065

8. Weill Cornell Graduate School of Biomedical Sciences, Cornell University, New York, NY 10065

9. Department of Medical Oncology & Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen 72076, Germany

10. DFG Cluster of Excellence 2180 “Image-Guided and Functional Instructed Tumor Therapy” (iFIT), University of Tuebingen, 72076 Tuebingen, Germany

11. Howard Hughes Medical Institute (HHMI), Memorial Sloan Kettering Cancer Center, New York, NY 10065

Abstract

Significance Efforts to understand and find new treatment options for high-grade serous ovarian cancer (HGSOC) have been confounded by a paucity of immune-competent models that accurately reflect the genetics and biology of the disease. Here, we leverage somatic tissue engineering to develop a fast and flexible immune-competent mouse model of HGSOC and reveal mechanistic insights into factors that dictate the response of ovarian tumors to conventional chemotherapy and immune checkpoint blockade. Our results identify a genotype-dependent therapy-induced senescence program that mediates sensitivity and resistance to first line chemotherapy and point to strategies to harness the senescence program to sensitize ovarian tumors to immune checkpoint blockade.

Funder

HHS | NIH | National Cancer Institute

HHS | National Institutes of Health

U.S. Department of Defense

EIF | Stand Up To Cancer

Deutsche Forschungsgemeinschaft

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3